Jarl Hellman
Dr. Jarl Hellman is a senior consultant in endocrinology and diabetes and Head of Diabetes at Uppsala University Hospital and has a long-standing commitment to improving diabetes care through both clinical practice and academic leadership. His work focuses on type 1 diabetes, particularly the use of continuous glucose monitoring (CGM) and smart insulin delivery systems. He has contributed to the development of national guidelines and quality improvement initiatives in diabetes care, including the award-winning IQ4 project.
Dr. Hellman has been a key investigator in several high-impact clinical trials, including the GOLD and SILVER studies, which evaluated the long-term effects of CGM in patients with type 1 diabetes treated with multiple daily insulin injections. In 2017, Dr. Hellman was named Diabetologist of the Year in Sweden by the Swedish Society for Diabetology (SFD), where he now serves as Chairperson. He is also a frequent contributor to international diabetes congresses such as EASD and ADA, where he shares insights on emerging technologies and clinical strategies. Dr. Hellman has acted as medical advisor and PI in a number of successful clinical trials at CTC.